News

When I look back on 2018, I see tremendous growth and progress in the field of NETs and in NETRF. We are proud of our role in this and grateful to the thousands of patients, families, and donors who joined us in the quest for better treatments and cures for neuroendocrine tumors. PRRT offers U.S. patients more options 2018 was off to a game-changing start when the FDA approved Lutetium 177 dotatate for gastrointestinal and pancreatic NETs—the first PRRT radiopharmaceutical approved in the United … read more

Elyse Gellerman, NETRF CEO, moderates a patient and caregiver panel during 2018 Chicago conference Making progress in NETs As we get ready to welcome 2019, we want to thank those who helped NETRF make 2018 so memorable. This year, with your help, we climbed mountains, reached new heights, and are ready for the next part of our journey to find better treatments and cures. Sparking Hope for NET patients When I think back on 2018, I see a person in the crowd—at an educational program or a support g … read more

Sixteen-year-old Haillie Koetter, Milwaukee, WI, was a busy high school sophomore maintaining honor-roll-level academics, playing junior varsity volleyball, and working part-time after school. And then she added neuroendocrine tumor research fundraising to her activities… In October 2017, Haillie’s stepmother, Esther— who hadn’t been feeling well—was having a lot of doctor appointments and tests. The 37-year-old mother of two and stepmother to Haillie was diagnosed with stage IV pancreatic neu … read more

Clarivate Analytics has released the most influential researcher list for 2018, which identifies exceptional researchers whose highly cited work is among the top 1% in their field around the world. Five scientists on the list are helping Neuroendocrine Tumor Research Foundation (NETRF) advance the world’s understanding of neuroendocrine tumors in search of improved treatments. The Boston-based nonprofit says it counts on elite, world-class scientific minds to accelerate progress in this rar … read more

With the end of 2018 just weeks away, life has moved into high-gear with holidays fast approaching and the many tasks that come with making the holidays special for family and friends. Along with holiday festivities, many of us are considering our year-end charitable gifts. Here at NETRF, our year-end is typically the busiest time of year for receiving donations and we are fortunate that so many include us when making their year-end gifts. We are preparing for a fun #GivingTuesday on November 27 … read more

If you’ve ever been tested for eyeglasses, you know how one lens can create grainy, foggy images and the next crisp, clear letters. That’s the kind of difference you can see between the Gallium-68 PET/CT scan and prior technology. But are these newer imaging techniques better? And who stands to benefit most from them? ... read more

Many patients and families facing a neuroendocrine tumor (NET) diagnosis wonder if they inherited the disease from their parents or if they can pass it down to their children. Most cases of NETs are not associated with hereditary risk factors. Researchers estimate that inherited factors may be associated in 17% of PNETs1 and 25% of pheochromocytomas and paragangliomas2. Other rates vary by primary site and subtypes of tumors. Knowing you have an inherited genetic risk factor won’t always have an … read more